69.19 +0.19 (0.28%)
After hours: 7:59PM EDT
|Bid||69.09 x 1200|
|Ask||69.19 x 1800|
|Day's range||68.98 - 70.81|
|52-week range||60.89 - 85.97|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||N/A|
|Earnings date||22 Oct 2020 - 26 Oct 2020|
|Forward dividend & yield||2.72 (3.79%)|
|Ex-dividend date||14 Sep 2020|
|1y target est||80.17|
The coalition of more than 30 state attorneys general called on the government to act or allow states to do so, saying in a letter to U.S. health agencies that Gilead "has not established a reasonable price" for remdesivir. "Gilead should not profit from the pandemic and it should be pushed to do more to help more people," the letter said.
Gilead Sciences (NASDAQ: GILD) beat Wall Street estimates when the big biotech announced its first-quarter results in late April. Last week, Gilead announced second-quarter results that were below analysts' expectations. Gilead has been in the news quite a bit in recent months thanks to the clinical success for its COVID-19 therapy remdesivir.
Gilead Sciences (NASDAQ: GILD) and Pfizer (NYSE: PFE) are two of the most competent pharmaceutical companies in the industry. Recently, Gilead has been in the headlines thanks to its much-discussed antiviral drug remdesivir, which appears to be somewhat beneficial for treating coronavirus infections in certain patient populations. It helps that Gilead was an attractive company well before the pandemic, with normalized trailing 12-month diluted earnings per share (EPS) of $3.90 in contrast with Pfizer's $1.98 and a robust profit margin of 21.8%, slightly trailing Pfizer's 28.8%.